Literature DB >> 32162240

Initiation of antipsychotics after moving to residential aged care facilities and mortality: a national cohort study.

Stephanie L Harrison1,2, Janet K Sluggett3,4,5, Catherine Lang3, Craig Whitehead6, Maria Crotty6, Megan Corlis7, Steve Wesselingh8, Maria C Inacio3.   

Abstract

BACKGROUND: There is a high burden of antipsychotic use in residential aged care facilities (RACFs) and there is concern regarding potential inappropriate prescribing of antipsychotics in response to mild behavioural symptoms. Antipsychotic use has been associated with a higher risk of mortality in community-dwelling older adults with dementia, but few studies have examined associations upon RACF entry. AIMS: To examine associations between incident antipsychotic use and risk of mortality for people with and without diagnosed dementia in RACFs.
METHODS: A retrospective cohort study, employing a new-user design (individuals did not receive an antipsychotic 6 months before enrolment) of 265,820 people who accessed RACFs in Australia between 1/4/2008 and 30/6/2015 was conducted. Cox regression models were used to examine adjusted associations between antipsychotic use in the first 100 days of RACF entry and mortality.
RESULTS: In the 100 days after entering care, 29,455 residents (11.1%) were dispensed an antipsychotic. 180,956 (68.1%) residents died [38,249 (14.4%) were related to cerebrovascular causes] over a median 2.1 years (interquartile range 1.0-3.6) follow-up. Of the residents included, 119,665 (45.0%) had a diagnosis of dementia. Incident antipsychotic use was associated with higher risk of mortality in residents with dementia (adjusted hazard ratio 1.20, 95% confidence interval 1.18-1.22) and without dementia (1.28, 1.24-1.31).
CONCLUSION: Initiation of antipsychotics after moving to RACFs is associated with a higher risk of mortality. Careful consideration of the potential benefits and harms should be given when starting a new prescription for antipsychotics for people moving to RACFs.

Entities:  

Keywords:  Antipsychotics; Dementia; Mortality; Nursing homes

Year:  2020        PMID: 32162240     DOI: 10.1007/s40520-020-01518-y

Source DB:  PubMed          Journal:  Aging Clin Exp Res        ISSN: 1594-0667            Impact factor:   3.636


  25 in total

1.  Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.

Authors:  Cheryl L P Vigen; Wendy J Mack; Richard S E Keefe; Mary Sano; David L Sultzer; T Scott Stroup; Karen S Dagerman; John K Hsiao; Barry D Lebowitz; Constantine G Lyketsos; Pierre N Tariot; Ling Zheng; Lon S Schneider
Journal:  Am J Psychiatry       Date:  2011-05-15       Impact factor: 18.112

2.  The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia.

Authors:  Victor I Reus; Laura J Fochtmann; A Evan Eyler; Donald M Hilty; Marcela Horvitz-Lennon; Michael D Jibson; Oscar L Lopez; Jane Mahoney; Jagoda Pasic; Zaldy S Tan; Cheryl D Wills; Richard Rhoads; Joel Yager
Journal:  Am J Psychiatry       Date:  2016-05-01       Impact factor: 18.112

Review 3.  Antipsychotic Use in Dementia.

Authors:  Julia Kirkham; Chelsea Sherman; Clive Velkers; Colleen Maxwell; Sudeep Gill; Paula Rochon; Dallas Seitz
Journal:  Can J Psychiatry       Date:  2016-10-08       Impact factor: 4.356

4.  Associations between the Drug Burden Index, Potentially Inappropriate Medications and Quality of Life in Residential Aged Care.

Authors:  Stephanie L Harrison; Lisa Kouladjian O'Donnell; Clare E Bradley; Rachel Milte; Suzanne M Dyer; Emmanuel S Gnanamanickam; Enwu Liu; Sarah N Hilmer; Maria Crotty
Journal:  Drugs Aging       Date:  2018-01       Impact factor: 3.923

5.  Antipsychotic Treatment Associated With Increased Mortality Risk in Patients With Dementia. A Registry-Based Observational Cohort Study.

Authors:  Emilia Schwertner; Juraj Secnik; Sara Garcia-Ptacek; Björn Johansson; Katarina Nagga; Maria Eriksdotter; Bengt Winblad; Dorota Religa
Journal:  J Am Med Dir Assoc       Date:  2019-03       Impact factor: 4.669

6.  Risk of death in elderly users of conventional vs. atypical antipsychotic medications.

Authors:  Philip S Wang; Sebastian Schneeweiss; Jerry Avorn; Michael A Fischer; Helen Mogun; Daniel H Solomon; M Alan Brookhart
Journal:  N Engl J Med       Date:  2005-12-01       Impact factor: 91.245

Review 7.  Living well in care homes: a systematic review of qualitative studies.

Authors:  Siobhan Aine Bradshaw; E Diane Playford; Afsane Riazi
Journal:  Age Ageing       Date:  2012-06-07       Impact factor: 10.668

8.  Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.

Authors:  Lon S Schneider; Karen S Dagerman; Philip Insel
Journal:  JAMA       Date:  2005-10-19       Impact factor: 56.272

9.  The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.

Authors:  Clive Ballard; Maria Luisa Hanney; Megan Theodoulou; Simon Douglas; Rupert McShane; Katja Kossakowski; Randeep Gill; Edmund Juszczak; Ly-Mee Yu; Robin Jacoby
Journal:  Lancet Neurol       Date:  2009-01-08       Impact factor: 44.182

10.  Impact of FDA black box advisory on antipsychotic medication use.

Authors:  E Ray Dorsey; Atonu Rabbani; Sarah A Gallagher; Rena M Conti; G Caleb Alexander
Journal:  Arch Intern Med       Date:  2010-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.